|Day Low/High||80.98 / 81.70|
|52 Wk Low/High||72.67 / 94.19|
The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Stocks ended higher on Tuesday.
Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.
The Dow Jones Industrial Average soars on Monday, and the S&P 500 posts a sharp increase as the Senate passes its version of U.S. tax reform.
Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.
Insiders are already looking beyond the upcoming merger to the patron saint of disruption Amazon.
The likes of CVS and Walgreens could suffer if Amazon follows through on reported talks it's held with Mylan and Sandoz to get its feet wet in the prescription drug retail market.
U.S. stock futures are pointing to losses for Wall Street on Friday, after the Senate delays a vote on its tax reform bill over deficit concerns.
The Switzerland-headquartered drug manufacturer is reportedly mulling a sale of its dermatology generics drug unit, which is based primarily in the U.S.
The FDA cleared GSK's new drug for fast-track development with quicker regulatory review.
State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.
Starbucks used to be a can't miss investment. But this year the stock has languished for a variety of reasons. Wall Street could get a scary wake-up call.
Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.
The European Central Bank may have lit a fourth quarter fire under Europe's M&A market.
Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.
Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.
Stock futures are lower on Monday as Mueller's Russia investigation takes its first concrete steps.
U.S. stock futures are lower on Monday.
Under the deal Novarits will make a cash offer of $41 a share for Nasdaq-listed AAA and $82 per American Depositary Share, subject to certain conditions, valuing AAA at $3.9 billion
Jim Cramer looks at Amazon, Alphabet, Intel and Microsoft and says his biggest problem in analyzing them is that they are such visionaries, he just can't keep up.
Jim Cramer is bullish on Baozun, Southwest Airlines Co., Union Pacific, CSX.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.